161 related articles for article (PubMed ID: 24313832)
1. Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.
Dillon R; Grimwade D
Leuk Lymphoma; 2014 Jul; 55(7):1444-6. PubMed ID: 24313832
[No Abstract] [Full Text] [Related]
2. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
[TBL] [Abstract][Full Text] [Related]
3. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
Mathews V; Thomas M; Srivastava VM; George B; Srivastava A; Chandy M
Haematologica; 2007 Jul; 92(7):994-5. PubMed ID: 17606455
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Asou N
Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
[No Abstract] [Full Text] [Related]
6. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
7. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama K
Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
[No Abstract] [Full Text] [Related]
8. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
Tajima M
Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
[No Abstract] [Full Text] [Related]
10. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
Spencer A; Firkin F
Aust N Z J Med; 1999 Jun; 29(3):385-6. PubMed ID: 10868510
[No Abstract] [Full Text] [Related]
12. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Komatsu N
Int J Hematol; 2014 Jul; 100(1):16-7. PubMed ID: 24912657
[No Abstract] [Full Text] [Related]
13. Scientists explore use of arsenic in therapy.
Miller M
J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
[No Abstract] [Full Text] [Related]
14. Arsenic: a new place?
Vincent PC
Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
[No Abstract] [Full Text] [Related]
15. Arsenic compound approved as cancer chemotherapy agent.
Miller JL
Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
[No Abstract] [Full Text] [Related]
16. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
Powell BL
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
[No Abstract] [Full Text] [Related]
17. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Au WY; Tam S; Fong BM; Kwong YL
Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
[No Abstract] [Full Text] [Related]
18. Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia.
Keyhani M
J Clin Oncol; 2012 Jan; 30(2):217; author reply 218-20; discussion 220-2. PubMed ID: 22124099
[No Abstract] [Full Text] [Related]
19. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
[No Abstract] [Full Text] [Related]
20. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Br J Haematol; 2001 Apr; 113(1):257-8. PubMed ID: 11360894
[No Abstract] [Full Text] [Related]
[Next] [New Search]